Anonymous ID: 1f4106 May 10, 2022, 5:59 a.m. No.16247312   🗄️.is đź”—kun   >>7588 >>7682 >>7696 >>7829 >>7939

>>16247258

This is in Dr. Oz district:

 

Dear Patient,

Due to unprecedented COVID-related supply chain disruptions in

China, all hospitals in the United States are experiencing a shortage of contrast media (sometimes referred to as X-ray dye) used to perform CAT or CT scans. This may affect ERCP procedures as well. As at all U.S. hospitals, LVHN and other imaging providers’ ability to perform these scans in all but the most critical cases will be limited until these supply chain issues are corrected. This shortage has been caused by the Chinese government’s COVID lockdown of Shanghai, where most of the world’s supply of contrast media is manufactured and then subsequently distributed by GE Healthcare and Bracco. This disruption is expected to last until at least the end of June.

 

LVHN is exploring various strategies to conserve contrast media, including using other imaging technologies and materials and postponing non-emergency scans. As always, we are 100% committed to providing the best possible care to our patients. If you have any questions or concerns about a scheduled test at LVHN, please contact the scheduling department at LVHN at 610-402-8378.

 

Facebook

LinkedIn

Website

Copyright © 2022 Eastern Pennsylvania Gastroenterology & Liver Specialists, All rights reserved.

You are receiving this email because you opted in via our website.

 

Our mailing address is:

Eastern Pennsylvania Gastroenterology & Liver Specialists

1501 N Cedar Crest Blvd

Allentown, PA 18104-2309

 

https://godlike.com/forum1/message5131871/pg1

Anonymous ID: 1f4106 May 10, 2022, 7:35 a.m. No.16247682   🗄️.is đź”—kun   >>7726

>>16247312

another hospital system EXACT same message….

 

https://www.slhn.org/blog/2022/important-message-regarding-global-shortage-of-contrast-media-for-scans

 

Important Message Regarding Global Shortage of Contrast Media for Scans

May 06, 2022

 

Dear St. Luke’s Patients,

 

Due to unprecedented COVID-related supply chain disruptions in China, all hospitals in the United States are experiencing a shortage of contrast media (sometimes referred to as X-ray dye) used to perform CAT or CT scans. As at all U.S. hospitals, St. Luke’s ability to perform these scans in all but the most critical cases will be limited until these supply chain issues are corrected. This shortage has been caused by the Chinese government’s COVID lockdown of Shanghai, where most of the world’s supply of contrast media is manufactured and then subsequently distributed by GE Healthcare and Bracco. This disruption is expected to last until at least the end of June.

 

St. Luke’s is exploring various strategies to conserve contrast media, including using other imaging technologies and materials and postponing non-emergency scans. As always, we are 100% committed to providing the best possible care to our patients. We will continue to keep you informed about this issue. If you have any questions or concerns, please call us at 1-866-STLUKES, option 2.

Anonymous ID: 1f4106 May 10, 2022, 7:47 a.m. No.16247726   🗄️.is đź”—kun

>>16247682

>Bracco

https://www.bracco.com/en/group

 

The Group

Bracco is an international Group active in the healthcare sector and a leader in diagnostic imaging. It has around 3,587 employees and annual total consolidated revenues of around 1,4 billion euros, 89% of which from international sales.In the Research and Development area, the company invests approximately 10% of reference turnover in the imaging diagnostics and medical devices sectors and has a portfolio comprising over 2,000 patents.PRODUCT PORTFOLIOThe Group’s main products are contrast agents, medical substances used to improve the diagnostic accuracy of biomedical imaging and the care of patients affected by diseases of varying type and severity. Contrast agents are routinely and widely used in all diagnostic imaging modalities, such as radiographic procedures, including computed tomography (CT), magnetic resonance imaging (MRI), ultrasound and nuclear medicine.GLOBAL COMMERCIAL PRESENCEBracco contrast media are sold in over 100 countries, both directly and indirectly through branches, joint ventures and licence and distribution agreements. Thanks to the quality and reliability of its products, the Group boasts leading positions in the most important geographical areas such as North America, China, Europe and Japan.RESEARCH AND INNOVATION IN DNAResearch and Development activities are concentrated in the laboratories in Geneva and Lausanne (Switzerland), Monroe and Silicon Valley (United States) and Italy (Colleretto Giacosa). Each research centre has specialised experience and expertise at the absolute cutting edge in different imaging modalities and operates in synergy with the medical and regulatory departments, whose operations are located in Milan (Italy), Konstanz (Germany), Paris (France), Monroe and Long Island (United States), Montreal (Canada), Mexico City (Mexico), São Paulo (Brazil), Beijing (China), and Tokyo (Japan).THE PRODUCTION ACTIVITIESThanks to constant investment in operating processes, Bracco has reached levels of excellence in quality, in full compliance with all applicable regulations in every country where it operates, and with special attention paid to ecologically sustainable production. The production activities of Bracco Imaging are carried out in Italy (Ceriano Laghetto, Torviscosa and Colleretto Giacosa), Canada (Montreal), Switzerland (Geneva), Germany (Singen), Japan (Saitama) and China (Shanghai).